When is National Bourbon Week? Here are 5 things to know and do to celebrate this year
Bardstown, the Bourbon Capital of the World, will host National Bourbon Week, held this year on June 9-15, a week-long event that pays tribute to the craftsmanship, heritage, and culture that make Bardstown the beating heart of the bourbon industry. National Bourbon Day is celebrated each year on June 14.
During National Bourbon Week, visitors and bourbon lovers canimmerse themselves in exclusive tastings, behind-the-scenes distillery experiences, special releases, and bourbon-inspired events throughout Bardstown. From engaging master distiller panels to curated cocktail experiences and live music, this celebration is a multi-day event for anyone who appreciates America's native spirit.
'As we kick off the second annual National Bourbon Week, we're proud to celebrate not only Nelson County's deep-rooted bourbon heritage but also the growing economic impact this event brings to our community,' Stacey Phelps, president of Visit Bardstown, said in a news release. 'This weeklong celebration is a true toast to the spirit, craftsmanship, and community that make us so special. Whether you're a seasoned enthusiast or just discovering your love for bourbon, there's no better place to be than Bardstown during National Bourbon Week.'
More: Looking for a new bourbon? Here are 18 new Kentucky bourbon, whiskies to try this month
This year's schedule includes a wide range of events with culinary offerings, cocktails, classes, tastings and more. Distilleries include Log Still Distillery, Bardstown Bourbon Company, Heaven Hill Distillery, James B. Beam Distilling Co., Preservation Distillery, Old SteelHouse Distillery, Lux Row Distillers, Maker's Mark Distillery, and Barton 1792 Distillery, all of which all planning special events for the week.
Here's what to know about the 2025 National Bourbon Week hel in Bardstown, Kentucky:
National Bourbon Week is a community-wide celebration of Bardstown, Kentucky and its ties to bourbon's history, growth and evolution. Home to some of the most iconic distilleries in the world, National Bourbon Week in Bardstown is more than just a festival — it's a tribute to the past, present, and future of bourbon.
The 2025 festival runs June 9-15.
New this year, Bourbon Capital Alliance's "The Mash Up" brings together its nine partner distilleries for a special evening at the just-opened Bespoke in Bond event space. "The Mash Up" will pair each distillery with a local culinary partner to showcase the distinctive flavors found in each distillery's unique mashbill. In addition, proceeds from a blind bottle pull that evening will be directed to a local community cause.
More: Here are 9 beer festivals taking place in Louisville this year
On Saturday, June 14, celebrate National Bourbon Day in downtown Bardstown with activities for all ages, including a brand-new Kids Zone offering free family fun.
For those of age, eight local distilleries will offer free samples from 12-4 p.m. For those who prefer something different, Bardstown Rotary Club will host a beer garden.
'We can't wait to welcome locals and visitors alike for a full day of celebration,' said Randi Mouser, executive director of Bardstown Main Street. 'Our downtown shops will be open and ready with great summer deals. '
For more information, a schedule of events and tickets, visit nationalbourbonweek.com.
Reach features reporter Kirby Adams at kadams@courier-journal.com.
This story was updated to add a gallery.
This article originally appeared on Louisville Courier Journal: National Bourbon Week 2025 celebration Bardstown Kentucky
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, announces significant changes within the Board of Directors. As mentioned in the press release dated July 29, 2025 following the agreement signed by Poxel and its directors with the senior creditor of the Company, and in the context of the filing for the insolvency (' déclaration de cessation des paiements ') and request for opening of reorganization proceedings (' redressement judiciaire ') with the Court for Economic Activities of Lyon, all the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn and Mr. Khoso Baluch, have submitted their resignations with immediate effect as of July 31, 2025. At its meeting on July 31, 2025, the Board of Directors of the Company decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe; Mr. Nicolas Trouche; Mr. Amit Kohli; Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Regarding the independence criteria adopted by the Board of Directors and derived from the MiddleNext Code, Ms. Sophie Jacq Lapointe and Mr. Amit Kohli are considered to be independent directors. As Mr. Alexandre Bragadir is an employee of IPF Partners, which is one of the Company's partners and creditors (but not a shareholder), he cannot be considered independent. Due to his appointment as Chief Executive Officer, Mr. Nicolas Trouche cannot be considered independent either. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors, as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Mr. Thomas Kuhn also informed the Board of Directors of his resignation from his position as Chief Executive Officer, with immediate effect as of July 31, 2025. The Board of Directors then unanimously appointed Mr. Nicolas Trouche as Chief Executive Officer of the Company. Sophie Jacq Lapointe With over 20 years of experience in the pharmaceutical industry, Sophie has held numerous executive roles and has contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Nicolas Trouche Nicolas started with D&I in 2021, a firm specialized in restructuring companies in special situations. Nicolas started in R&D and development of hardware components for robotics. He joined Valeo group where he developed a complete career in technical, project and division management positions in France, Germany and Spain. Moving to Faurecia, he managed the reorganization of one important plant within Seating Business Group. He started at Kuka in 2008 as CEO of Kuka Systems France to conduct the full restructuring of this company during subprime crisis, then managed participations of French and foreign investment funds in operational restructuring contexts, construction of green fields in Slovakia, Mexico and China, equity and build-up negotiations. In particular as CEO of a Tier 2 equipment group that he led from €70M to €150M in turnover. Senior advisor for a German fund, he also bought, managed and then sold companies in the BtoB service: industrial equipment, engineering services, electrical, PLC and Robotics. As a D&I partner, he has worked in several technology start-ups and has developed and restructured B2B industrial and commercial and service companies. Nicolas is an engineer in electrical engineering with a PhD in robotics. Amit Kohli Amit Kohli has over 3 decades of leadership experience operating at intersection of science, finance and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company's $75M sale to Medicus (NASDAQ: MDCX). Mr Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson and Sanofi, encompassing sales, marketing, finance, supply chain and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe. About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is otherwise not responsible for the content of external hyperlinks referred to in this press release.
Yahoo
4 days ago
- Yahoo
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
License agreement supports Madrigal's pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in-class MASH treatment in a once-a-day, well-tolerated pill CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ('Madrigal') today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) ('CSPC') for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026. 'We've made remarkable progress this year advancing our strategic priorities – from the continued successful launch of Rezdiffra, to securing new IP protection through 2044, to laying the groundwork for Rezdiffra's next stages of growth in F4c and Europe,' said Bill Sibold, Chief Executive Officer of Madrigal. 'This agreement to acquire global rights to SYH2086 aligns perfectly with our long-term goal to extend our leadership in MASH by building a pipeline anchored by Rezdiffra. We believe a combination of Rezdiffra and SYH2086 has the potential to deliver a best-in-class oral treatment for patients with MASH.' David Soergel, M.D., Chief Medical Officer of Madrigal, added, 'The clinical rationale for developing a combination therapy with Rezdiffra and an oral GLP-1 is clear: we want to optimize efficacy and tolerability in MASH by balancing the weight loss from a GLP-1 with the fibrosis and lipid reduction of Rezdiffra in a once-a-day pill. In the pivotal Phase 3 MAESTRO-NASH trial, even modest weight loss of five percent or more enhanced Rezdiffra's antifibrotic benefit, so we are confident that combination therapy with SYH2086 has the potential to provide increased efficacy for patients with MASH.' 'We are pleased to announce the in-license of our oral GLP-1 by Madrigal, an innovative company that pioneered the first approved treatment for MASH,' said Dongchen Cai, Chairman of the Board, CSPC. 'We believe Madrigal's strong clinical development and commercial capabilities will help unlock the full potential of SYH2086 to benefit patients.' Financial ConsiderationsUnder the agreement, CSPC has granted Madrigal an exclusive global license to develop, manufacture, and commercialize SYH2086. CSPC will receive an upfront payment of $120 million and is eligible to receive up to $2 billion in milestone payments if certain development, regulatory and commercial milestones are achieved, as well as royalties on net sales. CSPC may develop and commercialize other oral GLP-1 agonists in China subject to certain conditions. The transaction is anticipated to close in the fourth quarter of 2025, subject to the applicable regulatory clearance. About CSPC Pharmaceutical Group's SYH2086SYH2086, a preclinical candidate developed by the CSPC with complete global intellectual property rights, is a novel oral small molecule GLP-1 receptor agonist. GLP-1 receptor agonists are a class of drugs that exert their effects through the GLP-1 receptor and have been developed as treatments for the management of type 2 diabetes and obesity. Their core mechanisms of action include enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite, thereby offering both glycemic control and weight loss benefits. Preclinical data demonstrated that SYH2086 exhibited excellent in vitro agonistic activity as well as in vivo glucose-lowering and weight-loss effects, with a linear pharmacokinetic (PK) profile over a wide dose range across multiple animal species, with no significant safety risks observed. About MASHMetabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation, and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe. Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10-17 times higher risk of liver-related mortality as compared to patients without fibrosis. Those who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients. As MASH disease awareness improves and disease prevalence increases, the number of diagnosed patients with MASH with moderate to advanced fibrosis or compensated MASH cirrhosis (F2-F4c) is expected to grow. About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit Forward-Looking StatementThis press release includes 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to Madrigal's expected development timelines for SYH2086, the potential benefit of SYH2086 in combination with Rezdiffra, the anticipated timeline to close the licensing transaction and Madrigal's leadership position in the MASH sector. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; risks related to the parties ability to close the transaction in a timely manner or at all; risks associated with development of early stage candidates; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of Madrigal's clinical trials, including, but not limited to Madrigal's ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal's trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra's (resmetirom's) mechanism of action; market demand for and acceptance of Rezdiffra; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financing on acceptable terms; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitive trials; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; the timing and outcomes of clinical trials of Rezdiffra (resmetirom); the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal's submissions filed with the U.S. Securities and Exchange Commission('SEC'), for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and as updated from time to time by Madrigal's other filings with the SEC. Madrigal Pharmaceuticals, Inc. Investor ContactTina Ventura, IR@ Media ContactChristopher Frates, media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Yahoo
Madrigal Pharmaceuticals, Inc. (MDGL)'s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
We recently compiled a list of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It's FDA-approved drug, Rezdiffra (resmetirom), is the first oral, liver-targeted thyroid hormone receptor-β agonist for MASH with moderate to advanced fibrosis (F2–F3). It is also being tested in compensated MASH cirrhosis patients. At the 2025 EASL Congress, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented promising two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, showing Rezdiffra significantly reduced liver stiffness and lowered the risk of liver decompensation in F4c patients. Notably, 51% of participants had a ≥25% reduction in liver stiffness, and 65% of those with baseline portal hypertension moved to lower-risk categories. Safety remained consistent with prior results. Looking ahead, the MAESTRO-NASH OUTCOMES trial, expected to read out in 2027, will evaluate Rezdiffra's ability to reduce liver-related events in compensated cirrhosis patients. Meanwhile, regulatory momentum continues: the EMA's CHMP issued a positive opinion in June 2025, with potential EU approval expected by August. Rezdiffra would then be the first MASH treatment approved in both the U.S. and Europe. A healthcare professional wearing a health communications device discussing patient data with a colleague. Further solidifying its position, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) secured a new U.S. patent for Rezdiffra's dosing rights in July 2025, enhancing its intellectual property and global commercialization strategy. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
